Oncology Deal-Making The Daiichi Way

$13bn Deal Value In 18 Months

 
• By Ian Haydock

Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.

Monomethyl auristatin E (MMAE, vedotin), the cytotoxic payload of brentuximab vedotin antibody-drug conjugate. Atoms are represented as spheres with conventional color coding: hydrogen (white), etc
ADC Focus For Daiichi As It Pursues Oncology Goals • Source: Shutterstock

More from Business

More from Scrip